NAMS Valuation

NewAmsterdam Pharma Company NV

Add to Watchlist

Advanced Chart

26.800

-0.25(-0.924%)1D

Overview
Forecast
Valuation
Earnings

NAMS Relative Valuation

NAMS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NAMS is overvalued; if below, it's undervalued.

Historical Valuation

NewAmsterdam Pharma Company NV (NAMS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 2.57. The fair price of NewAmsterdam Pharma Company NV (NAMS) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：26.80

Fair

-14.81

Trailing

Forward

-11.41

EV/EBITDA

NewAmsterdam Pharma Company NV. (NAMS) has a current EV/EBITDA of -11.41. The 5-year average EV/EBITDA is 2.64. The thresholds are as follows: Strongly Undervalued below -12.99, Undervalued between -12.99 and -5.18, Fairly Valued between 10.46 and -5.18, Overvalued between 10.46 and 18.27, and Strongly Overvalued above 18.27. The current Forward EV/EBITDA of -11.41 falls within the Undervalued range.

-9.00

EV/EBIT

NewAmsterdam Pharma Company NV. (NAMS) has a current EV/EBIT of -9.00. The 5-year average EV/EBIT is -4.38. The thresholds are as follows: Strongly Undervalued below -10.55, Undervalued between -10.55 and -7.46, Fairly Valued between -1.30 and -7.46, Overvalued between -1.30 and 1.79, and Strongly Overvalued above 1.79. The current Forward EV/EBIT of -9.00 falls within the Undervalued range.

288.60

NewAmsterdam Pharma Company NV. (NAMS) has a current PS of 288.60. The 5-year average PS is 166.39. The thresholds are as follows: Strongly Undervalued below -256.46, Undervalued between -256.46 and -45.04, Fairly Valued between 377.82 and -45.04, Overvalued between 377.82 and 589.25, and Strongly Overvalued above 589.25. The current Forward PS of 288.60 falls within the Historic Trend Line -Fairly Valued range.

-17.19

P/OCF

NewAmsterdam Pharma Company NV. (NAMS) has a current P/OCF of -17.19. The 5-year average P/OCF is -8.18. The thresholds are as follows: Strongly Undervalued below -19.65, Undervalued between -19.65 and -13.92, Fairly Valued between -2.45 and -13.92, Overvalued between -2.45 and 3.29, and Strongly Overvalued above 3.29. The current Forward P/OCF of -17.19 falls within the Undervalued range.

-15.75

P/FCF

NewAmsterdam Pharma Company NV. (NAMS) has a current P/FCF of -15.75. The 5-year average P/FCF is -7.05. The thresholds are as follows: Strongly Undervalued below -16.46, Undervalued between -16.46 and -11.76, Fairly Valued between -2.35 and -11.76, Overvalued between -2.35 and 2.36, and Strongly Overvalued above 2.36. The current Forward P/FCF of -15.75 falls within the Undervalued range.

NewAmsterdam Pharma Company NV (NAMS) has a current Price-to-Book (P/B) ratio of 3.91. Compared to its 3-year average P/B ratio of 3.40 , the current P/B ratio is approximately 15.06% higher. Relative to its 5-year average P/B ratio of 0.55, the current P/B ratio is about 606.51% higher. NewAmsterdam Pharma Company NV (NAMS) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -5.90%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -5.90% , the current FCF yield is about -100.00% lower.

3.91

P/B

Median3y

3.40

Median5y

0.55

-4.14

FCF Yield

Median3y

-5.90

Median5y

-5.90

Competitors Valuation Multiple

The average P/S ratio for NAMS's competitors is 0.00, providing a benchmark for relative valuation. NewAmsterdam Pharma Company NV Corp (NAMS) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 740.06%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

NAMS.O

NewAmsterdam Pharma Company NV

Centessa Pharmaceuticals PLC

Loss

3.13B

AMRX.N

Amneal Pharmaceuticals Inc

Soleno Therapeutics Inc

Loss

3.01B

PBH.N

Prestige Consumer Healthcare Inc

Loss

-6.59%

3.13B

Performance Decomposition

Market capitalization of NAMS increased by 62.95% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 2.28M to 19.15M.

The secondary factor is the Margin Expansion, contributed -94.70%to the performance.

Overall, the performance of NAMS in the past 1 year is driven by Revenue Growth. Which is more sustainable.

740.06%

2.28M → 19.15M

Revenue Growth

-94.70%

-1.71K → -90.70

Margin Expansion

-582.41%

3.63 → -17.50

P/E Change

62.95%